Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ICLR market cap is almost 11B and cyto is less than 100m which is ridiculous low.
I have not seen holding up at this level for long time
James W. Harpel Partner Mr. Harpel invests in and helps build small and medium sized companies on a private equity basis. Jim is also a founder and General Partner of First Reserve Corporation, which acts as the General Partner of a series of private equity funds primarily in the energy and power industries totaling in excess of $12 billion. Progressive Employer Services, Insurance Congoleum Corp are among the leveraged buy-outs and private equity investments in which Jim has been actively involved. In addition, Jim is both a founder and the Chairman of Beanstalk Networks, a managed developer of mortgage software. https://www.pbcap.com/team/senior-management/james-w-harpel/
James W. Harpel
Partner
Mr. Harpel invests in and helps build small and medium sized companies on a private equity basis. Jim is also a founder and General Partner of First Reserve Corporation, which acts as the General Partner of a series of private equity funds primarily in the energy and power industries totaling in excess of $12 billion. Progressive Employer Services, Insurance Congoleum Corp are among the leveraged buy-outs and private equity investments in which Jim has been actively involved. In addition, Jim is both a founder and the Chairman of Beanstalk Networks, a managed developer of mortgage software.
https://www.pbcap.com/team/senior-management/james-w-harpel/
Form SC 13G/A CLEVELAND BIOLABS INC Filed by: HARPEL JAMES W owns 1.2m shares 9%
Form SC 13G/A CLEVELAND BIOLABS INC Filed by: HARPEL JAMES W owns 1.2m shares 9%
Thanks! You too, I added 250k shares on dips
I agreed! If Micheal is smart he would acquire IMUN now because later on it will be many other companies that would like to acquire/ reverse merger IMUN.
I’m sorry I meant other people!
Lol your calculations is ridiculous wrong. The equity stake could be 8.5%-10%, combined company
Lol learning from washed out/ pathetic losers
MANF is already licensed to emor for 33m shares. You mean reverse merger and new ceo
WTF if you don’t like company don’t invest. Lol you no one is forcing you.
Heavy volume
Bid size 1.25M
You have to added the debt to calculated the valuation. $7.66M MCAP +16M debt = $23.66M current valuation.
I like the company but they need to fired the ceo. He will destroy the company. He is a failure
Authorized Shares
990,000,000
01/21/2021
Lol it will probably be almost 1B OS
Yes same ceo
Convertible debt will keep the stock price low until it’s paid off. The revenue will not have huge impact on stock price. He is doing the same thing that he did with AMBS massive convertible debt e.g 45M
Reality vs fantasy GC needs to be fired or else the stock price will remain low
It’s waste of time talking about this company. The stock price will remain low until GC addresses the convertible debt. Another 18M shares were exercised. The OS now is 414,796,707
https://www.otcmarkets.com/stock/tomdf/security
Lol I hope so!
Cytocom presentation for next week. Noreen is not listed on management team
https://www.streetinsider.com/dr/news.php?id=17803243
Next week Presentation!
https://www.streetinsider.com/dr/news.php?id=17803243
The year is not over yet but MH said on conference the trial will start by end of the year and phase 3 trial of Crohns diseases will start in 1Q21.
No Joe I have been very bullish until now my friend. He has not changed at all from disaster of ambs. He keep doing the convertible debt and stock price will continue to drop. The company has incredible pipeline but they need to fire him.
wish you and your family a Merry Christmas, and good luck to you.
$CBLI $42M MCAP Ridiculously cheap
Robust pipeline:
Ph2 Covid19 Mild/Moderate Starting 12/20 (Global market $16B)
Ph3 CYTO-201-CROHNS starting 1Q21(Global market $12B)
Ph3 CYTO-401-Pancreatic Cancer starting 1Q21(Global market $3B)
$CYDY #COVID19 #COVID $HTBX $HGEN #biotech
I was very in the past but you have to realize that GC destroyed the company by doing toxic financing e.g convertible debt and the SP will remain low until all the convertible debt are converted into shares. Good luck to you but I’m out
Joe , why are you wasting your time posting GC tweets. the SP is trading below .10 and ambs SP .007. Is time to move on from this company
How do you know that ? 42M SO non stop dilution
It’s matter of time when Cytocom will acquire Imun. Imun own 15% of Cytocom which is huge.
Cytocom valuation
1B = 90M Imun
2B=180M Imun
JNJ paid 6.5B for autoimmune pipeline, only 1 phase 3 trial
Cytocom has to pull the trigger before trading next year.
added 198k shares@.0135
Every week OS keep increasing I think it’s time to move on. The stock price will remain low until 4.7M convertible debt is converted into shares.
$IMUN $CBLI 4Q2020- 1Q2021 potential milestone:
Phase 2 covid 19 trial to recruit patients with Mild/Moderate disease. The trial to start 12/2020 ($3B-5B)
Phase 3 trial Crohn disease to start in 1Q2021 ($12B market size). #Pennystocks #OTCSTOCKS #Covid19 $ibio https://t.co/5XYQxvzszH
$IMUN $CBLI Robust pipeline:
Ph2 Covid19 Mild/Moderate Starting 12/2020
Ph3 CYTO-201-CROHNS starting 1Q21
Ph3 CYTO-202 FIBROMYALGIA
Ph3 CYTO-203-Multiple Sclerosis
Ph3 CYTO-401-Pancreatic Cancer
#Pennystocks #OTCSTOCKS #COVID19 $BIIB $SRNE $AYTU #biotech $PFE $HTBX $CYDY $IBIO https://t.co/3F8W08ODdT
$CBLI $37M MCAP, 13M OS, Annual Meeting 12/18/20
Merger with Cytocom late stage Immune-Modulation Company: the merger to close 1QTR 21
Combined companies equity stake:
$IMUN 9% $CBLI 39% CYTO 52%
#Pennystocks #OTCSTOCKS #COVID19 $BIIB $SRNE $AYTU #biotech $PFE $HTBX $CYDY $IBIO
FYI new tweets posted today
Interesting OncBioMune Pharmaceuticals acquired Avant Diagnostics, Inc for 4.4 billion shares of OncBioMune’s common stock. Which AMBS owns 31% of Avant diagnostics, could receive 1.36B shares of $OBMP.